The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).
 
Lauren Shih
Stock and Other Ownership Interests - Exact Sciences (I)
Research Funding - Bayer HealthCare Pharmacuticals (Inst)
 
Vicky Wu
No Relationships to Disclose
 
Kevin Ng
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Ariana Dumenigo-Jimenez
No Relationships to Disclose
 
Jonathan R. Fromm
Research Funding - Merck
 
Renato G. Martins
Honoraria - Sanofi; Takeda
Research Funding - Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Other Relationship - Takeda; Takeda; Takeda
 
Keith D. Eaton
Research Funding - Mirati Therapeutics (Inst)
 
Rafael Santana-Davila
Consulting or Advisory Role - Amgen; AstraZeneca; Catalyst Pharmaceuticals; Genentech/Roche; Genentech/Roche; Mirati Therapeutics
Research Funding - Abbvie (Inst); Alpine Immune Sciences (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondSpring Pharmaceuticals (Inst); Daiichi Sankyo/Lilly (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst)
 
Christina S. Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Sylvia Lee
Research Funding - Bristol-Meyers Squibb (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); PACT Pharma (Inst); SeaGen (Inst); Tmunity Therapeutics, Inc. (Inst)
 
Diane Tseng
Research Funding - Gilead Sciences
Patents, Royalties, Other Intellectual Property - Use of Anti-CD47 Agents to Enhance Immunization, U.S. Patent Application No 16/048,862
 
Lei Deng
Honoraria - MJH Life Sciences; Precisca
Consulting or Advisory Role - Bristol-Myers Squibb; Regeneron
Travel, Accommodations, Expenses - MJH Life Sciences
 
Brittany Barber
No Relationships to Disclose
 
Emily Marchiano
No Relationships to Disclose
 
George E. Laramore
Stock and Other Ownership Interests - Pfizer
 
Jay Justin Liao
No Relationships to Disclose
 
Simon S. Lo
No Relationships to Disclose
 
Upendra Parvathaneni
No Relationships to Disclose
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Vaccitech
Research Funding - Adagene (Inst); AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); NCCN/Lilly (Inst); OncoC4 (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Sanofi/Aventis (Inst); Seagen (Inst)